Ajai Chari1, Myo Htut2, Jeffrey A Zonder3, Joseph W Fay4, Andrzej J Jakubowiak5, Joan B Levy6, Kenneth Lau7, Steven M Burt3, Brian J Tunquist8, Brandi W Hilder8, Selena A Rush8, Duncan H Walker8, Mieke Ptaszynski8, Jonathan L Kaufman9. 1. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. ajai.chari@mssm.edu. 2. City of Hope, Duarte, California. 3. Department of Oncology, Karmanos Cancer Institute, Wayne State University, Detroit, Michigan. 4. Baylor Research Institute, Dallas, Texas. 5. University of Chicago Medical Center, Chicago, Illinois. 6. Multiple Myeloma Research Consortium, Norwalk, Connecticut. 7. Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York. 8. Array BioPharma Inc, Boulder, Colorado. 9. Winship Cancer Institute, Emory University, Atlanta, Georgia.
Abstract
BACKGROUND: Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy with bortezomib was the rationale for the current phase 1 study. METHODS: The current study was a multicenter study with an initial dose-escalation phase to determine the maximum tolerated dose of 2 schedules of filanesib plus bortezomib with and without dexamethasone, followed by a dose-expansion phase. RESULTS: With the addition of prophylactic filgastrim, the maximum planned dose was attained: 1.3 mg/m2 /day of bortezomib plus 40 mg of dexamethasone on days 1, 8, and 15 of a 28-day cycle, with filanesib given intravenously either at a dose of 1.5 mg/m2 /day (schedule 1: days 1, 2, 15, and 16) or 3 mg/m2 /day (schedule 2: days 1 and 15). The most common adverse events (assessed for severity using version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events) were transient, noncumulative neutropenia and thrombocytopenia with grade 3/4 events reported in 44% (16% in cycle 1 with filgastrim) and 29% of patients, respectively. A low (≤11%) overall rate of nonhematological grade 3/4 toxicity was observed. With a median of 3 prior lines of therapy and 56% of patients with disease that was refractory to proteasome inhibitors, the overall response rate was 20% (55 patients), and was 29% in 14 patients with proteasome inhibitors-refractory disease receiving filanesib at a dose of ≥1.25 mg/m2 (duration of response, 5.2 to ≥21.2 months). CONCLUSIONS: The current phase 1 study established a dosing schedule for the combination of these agents that demonstrated a favorable safety profile with a low incidence of nonhematologic toxicity and manageable hematologic toxicity. The combination of filanesib, bortezomib, and dexamethasone appears to have durable activity in patients with recurrent/refractory multiple myeloma. Cancer 2016;122:3327-3335.
BACKGROUND:Filanesib is a kinesin spindle protein inhibitor that has demonstrated encouraging activity in patients with recurrent/refractory multiple myeloma. Preclinical synergy with bortezomib was the rationale for the current phase 1 study. METHODS: The current study was a multicenter study with an initial dose-escalation phase to determine the maximum tolerated dose of 2 schedules of filanesib plus bortezomib with and without dexamethasone, followed by a dose-expansion phase. RESULTS: With the addition of prophylactic filgastrim, the maximum planned dose was attained: 1.3 mg/m2 /day of bortezomib plus 40 mg of dexamethasone on days 1, 8, and 15 of a 28-day cycle, with filanesib given intravenously either at a dose of 1.5 mg/m2 /day (schedule 1: days 1, 2, 15, and 16) or 3 mg/m2 /day (schedule 2: days 1 and 15). The most common adverse events (assessed for severity using version 4.0 of the National Cancer Institute Common Terminology Criteria for Adverse Events) were transient, noncumulative neutropenia and thrombocytopenia with grade 3/4 events reported in 44% (16% in cycle 1 with filgastrim) and 29% of patients, respectively. A low (≤11%) overall rate of nonhematological grade 3/4 toxicity was observed. With a median of 3 prior lines of therapy and 56% of patients with disease that was refractory to proteasome inhibitors, the overall response rate was 20% (55 patients), and was 29% in 14 patients with proteasome inhibitors-refractory disease receiving filanesib at a dose of ≥1.25 mg/m2 (duration of response, 5.2 to ≥21.2 months). CONCLUSIONS: The current phase 1 study established a dosing schedule for the combination of these agents that demonstrated a favorable safety profile with a low incidence of nonhematologic toxicity and manageable hematologic toxicity. The combination of filanesib, bortezomib, and dexamethasone appears to have durable activity in patients with recurrent/refractory multiple myeloma. Cancer 2016;122:3327-3335.
Authors: Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson Journal: N Engl J Med Date: 2005-06-16 Impact factor: 91.245
Authors: S K Kumar; J H Lee; J J Lahuerta; G Morgan; P G Richardson; J Crowley; J Haessler; J Feather; A Hoering; P Moreau; X LeLeu; C Hulin; S K Klein; P Sonneveld; D Siegel; J Bladé; H Goldschmidt; S Jagannath; J S Miguel; R Orlowski; A Palumbo; O Sezer; S V Rajkumar; B G M Durie Journal: Leukemia Date: 2011-07-29 Impact factor: 11.528
Authors: Philippe Moreau; Halyna Pylypenko; Sebastian Grosicki; Ievgenii Karamanesht; Xavier Leleu; Maria Grishunina; Grigoriy Rekhtman; Zvenyslava Masliak; Tadeusz Robak; Anna Shubina; Bertrand Arnulf; Martin Kropff; James Cavet; Dixie-Lee Esseltine; Huaibao Feng; Suzette Girgis; Helgi van de Velde; William Deraedt; Jean-Luc Harousseau Journal: Lancet Oncol Date: 2011-04-18 Impact factor: 41.316
Authors: Shaji K Kumar; Terry M Therneau; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; S Vincent Rajkumar; Rafael Fonseca; Thomas E Witzig; John A Lust; Dirk R Larson; Robert A Kyle; Philip R Greipp Journal: Mayo Clin Proc Date: 2004-07 Impact factor: 7.616
Authors: Joseph T Opferman; Anthony Letai; Caroline Beard; Mia D Sorcinelli; Christy C Ong; Stanley J Korsmeyer Journal: Nature Date: 2003-12-11 Impact factor: 49.962
Authors: Jatin J Shah; Jonathan L Kaufman; Jeffrey A Zonder; Adam D Cohen; William I Bensinger; Brandi W Hilder; Selena A Rush; Duncan H Walker; Brian J Tunquist; Kevin S Litwiler; Mieke Ptaszynski; Robert Z Orlowski; Sagar Lonial Journal: Cancer Date: 2017-08-17 Impact factor: 6.860
Authors: Hans C Lee; Jatin J Shah; Lei Feng; Elisabet E Manasanch; Rebecca Lu; Ashley Morphey; Brandon Crumpton; Krina K Patel; Michael L Wang; Raymond Alexanian; Sheeba K Thomas; Donna M Weber; Robert Z Orlowski Journal: Blood Cancer J Date: 2019-10-01 Impact factor: 11.037
Authors: Darren Pan; Jonathan L Kaufman; Myo Htut; Manish Agrawal; Amitabha Mazumder; Robert F Cornell; Jeffrey A Zonder; Joseph W Fay; Manuel R Modiano; Erin L Moshier; Selena A Rush; Brian J Tunquist; Ajai Chari Journal: Cancer Med Date: 2021-12-17 Impact factor: 4.452